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Muscle cell differentiation ischaracterizedbythe synthesis ofcontractile proteins,
theirorganization in specialized structures, thesynthesisofenzymes ofspecific meta-
bolic pathways, and the inhibition ofcellproliferation(1). Activation ofmuscle-specific
gene expression is coupled to withdrawal from the cell cycle; therefore, much in-
terest has been focused on the roleofgrowth factors in thecontrol ofmuscle differen-
tiation (2-7). In skeletal muscle myoblasts, a reduction ofgrowth factor concentra-
tion causes a stop of DNA synthesis, withdrawal from the cell cycle, expression of
muscle-specific genes, and fusion ofthe myoblasts into multinucleated myotubes (7).
For smooth muscle cells (SMC)', the process is less distinctive on the cellular
level, since fusion never occurs. However, during the development of the arterial
tree, the acquisition ofdifferentiated features by SMC coincides with a decreased
and/or arrested replicative activity (8). Moreover, a reduction ofthe concentration
of serum added to SMC cultures leads to a partial reexpression ofmuscle-specific
mRNAs(9) and ofthe smooth muscle-specific isoform ofactinprotein, a-SM actin
(10, 11). Similarly, an increase in serumconcentrationisfollowed bydownregulation
ofa-SMactin expression andinductionofcell proliferation(10-12). This establishes
a negative relationship between exposure to growth factors and differentiation, but
it is unclear to what extent growth-inhibitory macromolecules affect differentiation
of SMC.
Interferons(IFNs) areimportant inhibitors ofcell proliferation, and differenttypes
of IFNs may be involved in both paracrine and autocrine growth regulation (13).
IFN-y is produced by activated T lymphocytes, and is released during the immune
response and in inflammatory conditions (13, 14). Arterial SMC respond to IFN-'r
by expression ofclass II MHC genes such as HLA-DR (15). These genes are ex-
pressed by SMC inthe vicinityofTcell infiltrates in experimentally injuredarteries
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and human atherosclerotic plaques, and this is probably due to a paracrine secretion
of IFN-y (15-18). This lymphokine is also a potent inhibitor of cell proliferation
in SMC cultures (18), and may be important as a negative growth regulator in vas-
cular lesions (18).
These observations raised the question as to whether IFN-y might also affect the
differentiation of SMC. One could, for example, hypothesize that the inhibition of
cell proliferation would be accompanied by a differentiation ofSMC. Wehave therefore
analyzed the effects of IFN-y on the expression of the a-SM actin gene. We found
that IFN-y inhibited the expression of a-SM actin at the mRNA level in parallel
with its inhibition of cell proliferation. Therefore, cessation of growth and expres-
sion of differentiation markers can be dissociated in SMC.
Materials and Methods
Reagents.
￿
Rat rIFN-y was kindly provided by Dr. Peter van der Meide, TNO Primate
Center, Rijswijk, The Netherlands. It was produced by CHO cells transfected with the chro-
mosomal IFN-y gene of the rat (19, 20). Polymyxin B and cycloheximide was purchased from
Sigma Chemical Co., St. Louis, MO.
Cells.
￿
SMC were isolated from the aorta of 6-wk-old Sprague-Dawley rats by collagenase
digestion as described (9, 18) and grown in RPMI 1640 medium with 10% FCS penicillin,
and streptomycin (Gibco Laboratories, Grand Island, NY). Primary cultures, and SMC grown
to passage 5 were used at subconfluent densities. They were treated with rat rIFN-y by addi-
tion to the medium for time intervals indicated in Results. Some cultures were also treated
with cycloheximide (10 A.g/ml) by addition to the medium. In some experiments, subconfluent
cultures were first synchronized in the Go phase of the cell cycle by incubation for 48 h in
medium containing 0.5% FCS and then induced to enter the cycle by addition of 10% FCS
in the presence or absence ofIFN--t and/or cycloheximide. IFN-y at 100 or 1,000 U/ml resulted
in maximal effects (see Results), and therefore, one of these concentrations was used in ex-
periments that did not include dose-response titrations.
RNA Isolation.
￿
10'cells in 80-cm' flasks were rinsed in PBS (150 mM NaCl, 10 mM phos-
phate buffer, pH 7.2), detached by trypsinization, and homogenized with a Dounce glass
homogenizer in 2.5 ml 6 M guanidine isothiocyanate, 0.1 M 0-mercaptoethanol, 5 mM so-
dium citrate, pH 7.0, 0.5% N-lauryl sarcosine (21, 22). RNA was isolated by ultracentrifuga-
tion on 4 ml 5 .7 M CsCl, 0.1 M EDTA, pH 7.4, as described (22), dissolved in 10 mM Tris-
HCl, pH 7.4, 5 mM EDTA, and stored at - 701C until analyzed.
RNA Analysis.
￿
Three different hybridization probes were used for the detection of actin
mRNAs. The plasmid pRAoaA-C contains a 320-bp DNA fragment corresponding to amino
acids 185-291 of a-actin inserted in the antisense direction in pSP65 and hybridizes to both
a-, J3-, and y-actin mRNAs (9). The pRAooA-3'UT construct carries a 130-bp insert that
corresponds to the 3' untranslated region ofa-SM actin mRNA cloned in the antisense direc-
tion in pSP64 (9). A probe prepared from this vector hybridizes exclusively to a-SM actin
mRNA. Synthesis of 32P-labeled RNAs complementary to the a-SM actin mRNA was
carried out under the conditions suggested by the enzyme manufacturer using linearized
pRAoaA-C or pRAoctA-3'UT plasmid DNAs, SP6 RNA polymerase (Boehringer Mann-
heim, Mannheim, FRG), and 32P-UTP (3,000 mCi/mmole; New England Nuclear, Boston,
MA; reference 23). The p91 plasmid is a cDNA clone corresponding to mouse skeletal muscle
a-actin mRNA (24). p91 DNA was labeled with 32P-dCTP (3,000 mCi/mmole; Amersham
International, Amersham, UK) using the random primer technique (25).
5 jigofcellular RNA was denatured in 50% formamide,separated by electrophoresis through
a 1.1% agarose gel containing 0.7% formaldehyde, and transferred to Hybond-C extra nitrocel-
lulose membranes (Amersham International) bycapillary blotting. After baking at 80°C over-
night, the membranes were prehybridized for 4 h at 580C with 50% formamide, 0.8 M NaCl,
50 mM Pipes, pH 6.8, 2 mM EDTA, 0.1 % SDS 2.5 x Denhardt's solution, 100 Rg/ml dena-
tured salmon sperm DNA, and 0.5 mg/ml yeast RNA (1 x Denhardt's solution is 200 Ag/mlHANSSON ET AL.
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polyvinylpyrrolidone, 200,ug/ml BSA, 200 Ag/ml Ficoll 400). Membranes were then hybrid-
ized overnight at 58°C with the appropriate cRNA probe at 106 cpm/ml in a new aliquot
ofprehybridization buffer. Washings were carried out in a washing apparatus (Hybaid, Ted-
dington, UK) at a flow rate of-30 ml/min. Membranes were washed with 1 liter of 3 x SSC
(1 x SSC is 150 mM NaCl, 15 mM sodium citrate), 2 x Denhardt's solution at 58'C, followed
by 1 liter of0.2 x SSC, 0.1% SDSy 0.1% sodium pyrophosphate at 780C, dried, and exposed
to Kodak XOmat AS film at -70°C overnight. Autoradiograms were scanned with a den-
sitometer (Shimadzu Corp., Kyoto, Japan) at 620 nm in the transmission mode, and the peak
area was used to estimate mRNA amounts. The size of mRNA species was calculated by
comparison with a 0.24-9.0 kb RNA ladder (Bethesda Research Laboratories, Gaitersburg,
MD).
Protein Ekctrophoresis.
￿
Cultures were rinsed twice in PBS containing 0.5 mM CaCl2 and
3 MM MgCl2, and collected in 1% SDS containing 20 mM dithiothreitol by scraping with
a rubber policeman. The samples were immediately sonicated and boiled for 3 min. Protein
concentration was determined according to Bradford (26). 40-Fcg amounts of protein were
separated on 10% SDS-PAGE gels (27), and stained with Coomassie blue. For quantification
of total actin, gels were scanned with a computerized laser beam densitometer (Genofit SA,
Geneva, Switzerland) as previously described (8). Actin isoforms were analyzed by two-
dimensional electrophoresis usingIEF in the first dimension (28). The pH gradient was es-
tablished with 2% preblended ampholines in the pH 4.0-6.5 interval (Pharmacia LKB Bio-
technology, Uppsala, Sweden), gels were loaded with 30 Rg ofproteins, and focused at 1,000
V for 16 h. A 10% SDS-PAGE was used for the second dimension and the gels were stained
with Coomassie blue. Quantification was performed by densitometric scanning ofthe stained
gels (8), and the relative amounts ofactin isoforms were expressed as percent of total actin.
Analysts ofActin Protein Synthesis.
￿
Cells (-106 cells/25-cm2 flask) were treated with 100 U/ml
IFN-y for 2 d, and incubated with 100 ACi 35S-methionine in methionine-free medium for
4 h. The cultures were then rinsed with PBS and trypsinized. Cytoskeletal extracts were pre-
pared by extraction with 0.5% Triton X-100, 150 mM NaCl, 50 mM Tris-HCI, pH 7.5, 1
mM EDTA, 1 mM PMSF, and 100 AM leupeptin (Sigma Chemical Co.) for 5 min on ice.
The insoluble extracts were treated with 25 pg/ml DNase I in PBS with PMSF and leupeptin
for 15 min at room temperature, and then solubilized in SDS sample buffer with 6.25%
a-mercaptoethanol. 105 cpm per sample was separated on two-dimensional electrophoresis
using IEF in the first direction and SDS-polyacrylamide electrophoresis in the second one
(28). The gels were fixed in Coomassie brilliant blue-acetic acid/methanol, destained, rinsed
in Amplify (Amersham International), and dried. Autoradiograms were made on Kodak
X-Omat AS film.
Immuno .fluorescence.
￿
The murine mAb anti-ceSM-1, which recognizes a unique epitope of
a-SM actin (29), was used. SMC were grown on glass coverslips, rinsed in PBS, fixed in ice-
cold acetone orethanol, preincubated with 2% normal horse serum, and then incubated with
anti-ceSM-1 at a concentration of 5 Ag/ml. After PBS rinses, the cells were incubated with
FITC-labeled anti-mouseIgG (Amersham International), rinsed, and mounted in PBS/glycerol
with P-phenylenediamine.
For double immunofluorescence, cells were rinsed in PBS, and incubated with rabbit
anti-total actin antibodies (29) at 80 Ftg/ml and anti-aSM-1 at 5 Ag/ml. FITC-conjugated
goat anti-rabbit IgG (Nordic, Tilburg, The Netherlands) and rhodamine-conjugated goat
anti-mouse IgG (Cappel Laboratories, Cochranville, PA) were used for the second step. Cells
were rinsed three times with PBS between incubations.
For desmin identification, an affinity-puified rabbit anti-desmin IgG (10) was used to a
concentration of0.025 pg/ml, followed by FITC-conjugated goat anti-rabbit IgG (Behring
Werke, Marburg, FRG), diluted 1 :20.
All antibodies were used at optimal dilutions as determined by checkerboard titrations.
Controls ofstaining specificity were performed by usingas first-step antibodies IgG fractions
ofrabbit and mouse serum at the same finalconcentrations as those ofthe specific antibodies.
For quantitation ofimmunofluorescence, 200 cells were counted in four fields ofeach culture,
and four cultures used in each experiment.
Analysis ofCell Proliferation.
￿
Cells were grown in 96-well Microtiter plates. IFN-y was added1598
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during exponential growth, and the wells were analyzed for cell protein by a dye-binding
method, as described (18), at various time points afteraddition ofIFN. The plates were read
in a microtiter photometer (EAR400; SIT, Salzburg, Austria). Total DNA content was de-
termined as described by Burton (30).
Analysis ofI-A Expression.
￿
Cells were grown in 96-well Microtiter plates, stimulated with
IFN --f, fixed, and analyzed for cell surface expression of the rat class II MHC antigen I-A
by a cell surface ELISA method (18) using the mAb OX6 (Seralab, Crawley Down, UK).
Results
Cell Growth.
￿
IFN-yinhibited proliferation of arterial SMC as revealed by a reduc-
tion of total cell protein in the culture dishes (Fig. 1). The growth inhibition was
paralleled by an induction of the class II MHC antigen, I-A (Fig. 1), and was depen-
dent on dose and time of IFN-y incubation (Fig. 1).
The total DNA content was estimated in SMC cultures in which 109 cells at fifth
passage had initially been plated in 35-mm Petri dishes. The cultures were treated
in 5 d with 1,000 U/ml IFN-y, and cell numbers were calculated based on a DNA
content per cell of N6 pg (8). Using this determination, 1.5 x 10 6 cells were present
in IFN-y-treated cultures, whereas control cultures contained 3 x 10 6 cells.
Actin andDesmin Organization.
￿
Immunolluorescence studies using actin antibodies
of different specificities were performed to evaluate IFN-y effects on the organiza-
tion of cytoplasmic actin. Antibodies to total actin mainly decorated stress fibers
(Fig. 2 a). The number of cells positive for the u-SM actin antibody, anti-aSM-1
(Fig. 2 b), was greater in primary cultures (64%) than in SMC at passage 5 (44%).
After treatment with IFN-y, SMC were always stained with anti-total actin anti-
bodies (Fig. 2 c), but the number of ot-SM actin-positive cells decreased dramati-
cally. Many cells were negative, particularly in SMC at passage 5 (Fig. 2 d), and
positive cells were moderately or weakly stained. The proportion of positive cells
in IFN-y-treated cultures was 35% in primary SMC and 15% in SMC at passage
5 . Desmin-positive cellswere present exclusively in primary SMC cultures (10). In-
terestingly, the percentage of desmin-positive cells (51%) was the same in untreated
and IFN-treated cultures.
The effects of cell density and growth state on ct-SM actin were further studied
in passaged cells. To evaluate different phases ofthe cell cycle, SMC were synchronized
in Go by serum starvation and then induced to enter the cell cycle by addition of
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FIGURE 1.
￿
IFN-y inhibits prolif-
eration and induces I-A antigen in
a dose-dependent way. SMC (pas-
sage 5) were grown for 2 d in mi-
crotiter plates containing medium
with IFN-y. Cellnumberswere de-
termined from cell protein analysis,
and I-A expressionfrom acell sur-
face ELISA. Coefficients of varia-
tion were <2%.HANSSON ET AL .
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FIGURE 2 .
￿
IFN-y selectively eliminatesa-SM actin stress fibers. SMC at passage 5were grown
for 5 d in regular medium (a and b) or in medium containing IFN-'Y at 1,000 U/ml (c and d).
Actinwas visualized by double-staining immunolluorescence usinga rabbit antibody that recog-
nizes all actin isoforms (a and c) and a mouse mAb that specifically recognizes a-SM actin (b
and d) ( x200) .
serum . The frequencyofa-SM actin-positive cells was slightly reduced in prolifer-
ating cells when compared with quiescent ones, and the reduction was more promi-
nent in the S and G2 phases (Fig . 3) . ci-SM actin-positive cells were significantly
reduced in all IFN-y-treated cultures irrespective of cell cycle conditions (Fig. 3).
Therefore, the reduction in ci-SM actin expression observed in IFN-y-treated cells
is not secondary to cell cycle effects.
The IFN-y-induced reduction ofct-SM actin-expressing cells was (at least par-
FIGURE 3.
￿
The IFN-y effect on a-SM actin is
notdue to cell cycle effects.SMC(passage 5)were
made quiescent in 0.5% FCS for 2 d, and then
stimulated to enter the cell cycle by addition of
10% FCS without (a-d) or with (t-h) IFN-y (100
U/ml). They were analyzed fora-SM actin stress
fibers by immunofiuorescence at various time
points corresponding to different phases in the
cell cycle. Data are expressed as cells containing
a-SM actin stress fibers as percent oftotal cells
(mean t SEM, n = 4) . (a) Cells in 0.5% FCS,
corresponding to Go ; (b) 12-h incubation in 10%
FCS(corresponding to GI); (c) 24 h in 10% FCS
(corresponding to S); (d) 36 h in 10% FCS(mainly
G2) ; (e)0.5% FCS + IFN-y for 36h (i.e., in Go);
(1) 10°% FCS for 36 h, IFN-y added after 24 h (i .e., IFN-y was added during S phase) ; (g) 10% FCS
for 36 h, IFN-y added after 12 h (i .e ., IFN-y was added during GI); (h) 10% FCS and IFN-y, both
for 36 h (i .e., IFN-y was added at the Go/Gl transition) .1600 INTERFERON y CONTROLS SMOOTH MUSCLE ACTIN EXPRESSION
FIGURE 4 .
￿
IFN-y effect on a-SM actin is atleast
partially reversible. SMC(passage 5) were treated
withIFN-'y (100 U/ml) for 7 d, and then switched
to freshmedium either with (X) or without(N)
IFN-.y . Controls (p) received fresh medium
withoutIFN-,y throughout the 14dofthe experi-
ment. All cells were analyzedfora-SM actin stress
fibersby immunofluorescence . Values are percent
a-SM actin fiber-containing cells (mean t SEM,
n = 4) .
tially) reversible, since withdrawal of IFN-,y resulted in an increase in a-SM actin
levels towards control values (Fig . 4) . It is unlikely that the effect was due to con-
taminating endotoxins, since addition of polymyxin B did not significantly affect
a-SM actin content (Fig . 5) .
Cellular Actin ContentandSynthesis.
￿
Quantitative changes in actin were examined
by densitometric analysis of SDS-PAGE gels (data not shown) . Actin represented
15% of total cellular protein in primary control SMC, but decreased to 8.3% after
IFN- ,y treatment (1,000 U/ml for 5 d) . A decrease in the percentage of actin per
total protein occurred betweenprimary culture(15%) and passage 5 (12%), andthis
was further decreased by IFN-,y treatment (to 9.1%) .
The proportion ofa-SM actin per total actin was studiedby two-dimensional elec-
trophoresis . Cultured SMC always showed a /3-actin predominance (Fig. 6 a) . After
exposure to IFN-y, the a-SM actin spotwas selectively diminished both in primary
cultures (Fig. 6 b) and in cultures at passage 5 . Quantitative evaluation of the rela-
tive proportions of the isoforms showed that IFN-,y treatment reduced a-SM actin
content both in primary and passaged cultures, with a concomitant increase in 0-
and y-actin isoforms (Table I) .
To better understand the effects of IFN-,y on actin isoform expression in cultured
SMC, we calculated the total protein, total actin, and single actin isoform contents
as pg/cell (8) in control and IFN-y-treated SMC during primary cultures and at
passage 5. During primary cultures, the totalprotein content per cell didnot change
in IFN-y-treatedSMC (264 pg) compared with control SMC (262 pg). Total actin
FIGURE 5 .
￿
IFN-y effect on a-SM actin is not
due to endotoxin contamination. SMC (pas-
sage 5) were treated for5d with IFN- ,y at 100
U/ml and/or polymyxinB at 10 jig/ml (mean
t SEM, n = 4) .HANSSON ET AL.
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decreased from 54.3 to 37 pg; a-SM actin content decreased from 13 to 3 .7 pg, and
i8- and y-actins also decreased slightly (30 vs . 26 pg for (3 and 10 vs . 8 pg for y) .
Interestingly, in SMC at passage 5, IFN-y increased total protein content per cell
from 262 pg in controlSMC to434pg in ON-y-treatedSMC. We haveno explana-
tion for the different actions ofIFN-y on the total protein content of primary and
passage 5 SMC. Total actin increased from 31.9 to 39.7 pg; despite this slight in-
crease, a-SM actin content decreased from 3.6 to 2.6 pg while (3- andy-actins in-
creased, respectively, from 22.3 to 29.2 pg and from 6.9 to 7.9 pg .
The synthesis of actin isoforms was analyzed by two-dimensional electrophoresis
after metabolic labeling ofSMC with 35S-methionine (Fig. 6 c) . Treatment with 100
U/ml IFN-y for 2dwas sufficient to significantly inhibit the synthesis of the a-actin
isoform (Fig. 6 d).
Actin mRNA Content.
￿
The striking effects on actin protein synthesis and content
stimulated us to further investigate the expression of the actin gene family at the
mRNA level. 32P-labeledRNA synthesized with pRAoaA-CDNA as a template hy-
bridizes to both a-, /3-, and -y-actin mRNAs, which have large sequence homologies
TABLE I
IFN-y Reduces a-SM Actin Protein Content
FIGURE 6 .
￿
a-SM actin protein content andsyn-
thesis is reduced by IFN-y . Protein extracts of
untreated (a) or IFN-y-treated (1,000 U/ml, 5 d)
(b) SMCwere analyzed by two-dimensional elec-
trophoresis . UntreatedSMC show a predomi-
nance of fl-actin content, a-SM and y-actin iso-
forms having Coomassie blue-stained spots
comparable in size (a). In SMC treated with
IFN-y (b), thea-SM actin spot is clearly reduced.
For analysis of actin synthesis, control SMC (c)
andIFN-y-treatedSMC (d) were metabolically
labeled with 35S-methionine, and analyzed by
two-dimensional electrophoresis followed by au-
toradiography. In IFN-y-treated cells, there is a
clear reduction of the a-SM actin spot (d) .
SMC in primary culture or fifth passage were treated with IFN-y(1,000 U/ml,
5 d) andanalyzed by densitometric scanning of two-dimensional electrophoresis
gels . Values are expressed as percent of total actin content .
SMC culture Treatment a
Actin isoforms
/3 'r
Primary 0 24 57 19
Primary IFN-y 10 69 21
Passage 5 0 11 71 19
Passage 5 IFN-y 6.6 74 201602
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(9). Two bands of 2 .1 and 1.7 kb were seen in Northern blots of total SMC RNA,
corresponding to the 0 + y (2.1 kb) and ci (1.7 kb) mRNAs, respectively (Fig. 7,
lane a) . In IFN--y-treated cells, the 1.7-kb band was significantly reduced, and there
was also a slight reduction of the 2.1-kb band (Fig . 7, lane b) . Similar results were
obtained using the p91 total actin cDNA probe (24) .
The reduction of the 1.7-kb c>:-actin mRNA species was confirmed with the use
of the ct-SM actin-specific cRNA probe derived from pRAociA-TUT. This plasmid
consists ofa 130-bp sequence from the 3' untranslated region ofa-SM actinmRNA
and the cRNA probe is specific for this mRNA species (9) . Fig . 7, lanes c and d,
show Northern hybridization of total RNA from control SMC (lane c) and SMC
treated with 1,000 U/ml IFN-y for 5 d (lane d) .
Effects on a-SM actinmRNA levels were further evaluated by densitometric scan-
ning of Northern blots . A significant reduction of a-SM actin mRNA was detect-
able after 12h oftreatment with IFN-y, and was even more strikingwhen treatment
continued for 24-72 h (Fig . 8). IFN-y treatment in a concentration range of50-1,000
U/ml caused a dose-dependent inhibition of a-SM actin mRNA (Fig. 9) .
The IFN-y-induced reduction ofa-SM actinmRNA was abolished by cyclohexi-
120 ,
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FIGURE 7 .
￿
IFN-'y reduces the steady-state level ofa-SM
actinmRNA . Northern blot oftotalRNA from control (a
and c) or IFN-y-treated (1,000 U/ml, 5d) (b and d) SMC
in primary culture, hybridized with the total actin probe
PRAoaA-C (a and b) or with thea-SM actin-specific probe
PRAoctA-3'UT (c and d) . The 2.1-kb bands correspond to
cytoplasmic (9 + y) mRNAs, while the 1.7-kb bands cor-
respond to a-SM actin mRNA. ControlSMC expressa-SM
predominance (a). After incubation with IFN-y, the 1.7-kb
band is clearly reduced . A decrease in cytoplasmicRNAs
is also present (b) . Hybridization with pRAociA-3'UT shows
an almost complete disappearance ofa-SM actin mRNA
in IFN-y-treated SMC (d) as compared with controls (c).
FIGURE 8 .
￿
Inhibition ofa-SM actinmRNA is
dependent on time of IFN-'y treatment . SMC
were incubated with IFN-y at 1,000 U/ml for 3,
6, 12, 24, or 72 h . Total RNA was separated by
agarose electrophoresis in formaldehyde anda-SM
actinmRNA analyzed by hybridization withthe
a-SM actin-specific probe PRAoaA-3'UT and
quantitated by densitometric analysis of auto-
radiograms . Data are given as percent ofmRNA
levels in untreated controlSMC (mean t SEM,
n=3).HANSSON ET AL .
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FIGURE 9 .
￿
Dose dependency ofIFN-y-induced inhibition
ofa-SM actin mRNA. Cells were incubated for 72 h with
IFN-y at 0, 50, 100, or 1,000 U/ml . a-SM actin mRNA
was analyzed by hybridization withPRAoaA-3'UTfollowed
by densitometric scanning. Data are given as percent of
mRNA levels in untreated control SMC.
FIGURE 10 . IFN-y-induced inhibition of a-SM actin
mRNA is dependent on protein synthesis . Cells were in-
cubated for 12 h with IFN-y at 1,000 U/ml in the presence
or absence of cycloheximide (CHX) at 10 Kg/ml . Hybrid-
ization was with the a-SM actin mRNA-specific probe
PRAociA-TUT .
mide treatment, indicating that the inhibitory effect of IFN-'y on a-SM actin gene
expression was dependent on protein synthesis (Fig. 10) .
Discussion
Inflammatory mediators controlphenotypic expression in the cells of theimmune
system. IFN-y upregulates or induces expression ofclass IIMHC antigens in mac-
rophages and other APC, and also serves as an activator of macrophages (31) . It
is secreted by activatedT lymphocytes, and it is therefore conceivable that IFN-y
plays an important role in the immune response .
The effects ofIFN-y on cells not normally involved in the immune response have
been more controversial . It is, however, now clear that IFN-y has an intrinsic an-
tiproliferative activity, since both natural and recombinant IFN-y inhibits growth
ofmany cell types, includingSMC (18, 32-33) . It acts by blocking the progression
of the cell through the Gt phase of the cell cycle (18, 34) .
Recent observations suggest that IFN-y also affects the expression of genes not1604
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directly related to proliferation in mesenchymal cells. We and others have shown
that expression ofclass II MHC antigens in SMC, fibroblasts, endothelial cells, and
several othertypes ofcells is induced by IFN--y (16-18, 35, 36). In fibroblasts, IFN-y
also inhibits collagen production (37-39) and thechemotacticresponse to fibronectin,
platelet-derived growth factor, and leukotriene B4 (40).
The inhibitory effect of IFN-y on a specialized function of SMC and fibroblasts,
such as collagen production, suggests that IFN-y may affect the differentiation of
these cells. This possibility has now been tested and our data show that IFN-'Y in-
hibits the expression of smooth muscle-specific a-actin. The effect is seen on both
mRNA and protein levels, and our data suggest that the primary effect might be
on the transcription of the a-SM actin gene. This probably requires the synthesis
of an inhibiting protein, since cycloheximide reversed the effect of IFN-'Y on a-SM
actinmRNA. An alternative explanation wouldbe that IFN-y induces the synthesis
of a protein that degrades a-SM actin mRNA.
The inhibition of a-SM actin mRNA expression induced by IFN-'r was followed
by a reduced synthesis of the a-SM actin protein. The changed balance in the syn-
thesis of actin isoforms resulted in a reorganization of the cytoskeleton, indicated
by areduced number ofa-SM actin-containing stress fibers in cellsexposed to IFN--y.
It appears likely that such aloss of specialized contractile structures would adversely
affect the contractile capacity of SMC.
It is noteworthy that while IFN-y decreases a-SM actin content per cell, it does
not affect the number of desmin-positive cells in primary cultures, suggesting that
its action is exerted specifically on actin genesbut notgenerally on SMC cytoskeletal
differentiation.
Two observations suggestthat the inhibition of a-SM actin expression is not sec-
ondary to the cell cycle block. First, the reduction of a-actin mRNA occurred al-
ready 6-12 h after addition of IFN-y. Second, the effect of IFN-y on a-SM actin
stress fibers was observed in all cell cycle phases. In contrast, IFN-y must be added
within 9 h after entry into the cell cycle in orderto block DNA replication (18). Our
results therefore suggest that IFN-y may have two independent effects: one that in-
hibits cell cycle progression andanotheronethat inhibits a-SM actin gene expression.
This conclusion is further supported by the observation (41) that heparin, another
inhibitor of SMC proliferation, increases the level of a-SM actin mRNA and pro-
tein during the arterial response to injury in vivo. Heparin, however, does not ap-
pear to act on a-SM actin isoform expression per se, since its effects on actin can
be explained by the block in cell cycle progression caused by this drug (41).
Previous work has shown that the control of actin isoform expression in SMC
is complex; thus, a-SM actin protein is less readily degraded than /3 and y actin
isoforms (42). Moreover, in the normal rat aorta (42) and carotid artery (41), as
well as in primary cultures of SMC (9, 42), the proportion of a-SM actin mRNA
over total actin mRNA is significantly higher than the proportion of a-SM actin
protein over total actin protein synthesized in vivo. This suggests that under basal
conditions, some of the a-SM actin mRNA is not translated. The present results
indicate that another type of control over a-SM actin expression is exerted on the
steady state level of mRNA, and that this level can be modulatedby IFN-y. In myo-
blasts of striated muscle, TNF has been reported to exert a similar type of controlHANSSON ET AL.
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ona-actinmRNA(43). This alsosupportstheconcept that cytokinesoftheimmune
system can modulate gene expression in mesenchymal cells.
Inductionofdifferentiation is usually associated with a reducedproliferation, and
viceversa, an increased proliferation is usually accompanied by amore dedifferen-
tiated phenotype. This simple patterndoesnot holdtrue in the caseofIFN-y stimu-
lation of SMC, since both proliferation and expression ofthe differentiated pheno-
type are inhibited. Instead, IFN-y should probably be considered as a regulator
ofthe expression ofspecific genes in mesenchymal cells. The combination ofan in-
hibition ofdifferentiatedSMC properties together with an induction ofclassIIMHC
antigens makes it tempting to speculate that the net effect of IFN-y could be an
adaptation of the SMC phenotype during local inflammatory responses.
Summary
Differentiationofmuscle cellsischaracterized morphologicallybythe acquisition
ofcontractile filaments and characteristic shape changes, and onthe molecularlevel
by inductionoftheexpression ofseveralgenes, includingthosefor themuscle-specific
a-actin isoforms. IFN-y is an inhibitor of proliferation for several cells, including
vascular smooth muscle, and is also an inducer ofdifferentiated properties for sev-
eral hematopoietic cells. We have therefore investigated whether IFN-y affects the
expression ofa-smooth muscle actin in cultured arterial smooth muscle cells. Cells
exposedto IFN-yshow a reduction ofa-smooth muscle actin-containing stress fibers,
as detected byimmunofluorescence. Theeffect wasobserved in all phases ofthecell
cycle, and was caused bya reduction ofthesynthesis ofa-smooth muscle actin pro-
tein as revealed bytwo-dimensional electrophoretic analysisofactin isoforms. RNA
hybridization usinga cRNAprobe that hybridizes to all actin mRNAs showed that
IFN-y-treatedcellshaveareducedcontentofthe 1.7-kbmRNA thatcodes fora-smooth
muscle actin, and to a lesser extent, also ofthe 2.1-kb mRNA encoding the /3 and
y-cytoplasmic actins. The reduction ofa-smoothmuscle actinmRNAwas confirmed
using an a-smooth muscle actin-specific cRNA probe. The reduction ofa-smooth
muscle actin mRNAoccurs within 12 h, and isdependent on protein synthesis, since
cycloheximide treatment reversed the effect. The inhibition ofthis mRNA species
was dose dependent, and detectable by RNA hybridization at a dose of 50 U/ml
IFN-y. These results suggest that the differentiation ofarterial smooth muscle cells
is not necessarily coupled to an inhibition ofcellular proliferation. Instead, IFN-y
may regulate the expression of several genes that control both proliferation and ex-
pression of differentiation markers.
We thank Marianne HAden fortechnical assistance and Dr. Peter van derMeide for kindly
providing recombinant rat IFN-.y.
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